Teva Pharma (TEVA) Tops Q1 EPS by 28c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Reports First Quarter 2018 Financial Results
May 3, 2018 7:00 AM EDTRevenues of $5.1 billion Free cash flow of $1.9 billion GAAP EPS of $1.03 Non-GAAP EPS of $0.94 Restructuring plan on-track to achieve $1.5 billion of savings in 2018 and $3.0 billion by the end of 2019 Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.40-2.65 from $2.25-2.50 Free cash flow guidance raised to $3.0-3.2 billion from $2.6-2.8 billion
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical... More
